Cipher Pharmaceuticals Inc.

TSX:CPH.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$13.05 +0.94%

+$0.15 today

Market cap
$331.67M
Beta
0.48
P/E (TTM)
9.3
EPS (TTM)
$1.22
52W Low $11.98High $20.56

Volume 0.04M

Average 0.03M

CPH.TO EBITDA Margin

EBITDA as a percentage of revenue.

Cipher Pharmaceuticals Inc.TSX: CPH.TO

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 59.2%

EBITDA Margin was 59.2% in Q1 FY2026, up 23.4 pp from a year earlier. On a trailing-twelve-month basis it was 49.3%, up 16.9 pp year over year. Over 3 fiscal years it narrowed by 11.3 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 65.8% for the fiscal year ending Dec 2026, up from 46.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
59.2%+24.8 pp QoQ
Last fiscal yearDec 2025
46.9%+11.4 pp YoY
LTMMar 2026
49.3%+16.9 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+23.4 pp+3.8 pp-19.6 pp
1 year+11.4 pp+18.9 pp+7.5 pp
3 years-11.3 pp-2.1 pp+9.2 pp
5 years-2.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
46.9%
Year-over-year change
+11.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How CPH.TO compares with its peers on the latest reported figures

  • CPH.TO's LTM Mar 2026 EBITDA Margin of 49.3% is the highest of the 8 companies compared; the peer median is -10.5%.
  • Its year-over-year change of +16.9 pp is the 4th highest of 8, against a peer median of -5.8 pp.
  • Over three fiscal years its change of -11.3 pp compares with a peer median of +82.9 pp.
CPH.TO Competitors Peer median
EBITDA Margin for CPH.TO and competitors
Company Period LTM level YoY 3-year change
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 202649.3% +16.9 pp-11.3 pp
TSND.TOTerrAscend Corp.LTM Mar 202623.1% +19.6 pp+126.3 pp
GUD.TOKnight Therapeutics Inc.LTM Mar 202612.8% -5.8 pp+3.5 pp
ACB.TOAurora Cannabis Inc.LTM Mar 20263.1% -11.9 pp+39.6 pp
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026-10.5% +23.0 pp+1464.5 pp
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026-14.9% -18.5 pp—
WEED.TOCanopy Growth CorporationLTM Mar 2026-20.4% +157.8 pp+798.1 pp
EDT.TOSpectral Medical Inc.LTM Mar 2026-1275.3% -390.0 pp-37.5 pp
Peer median (excluding CPH.TO) -10.5%-5.8 pp+82.9 pp

Competitors are the stored peer set for CPH.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue21.94M20.68M21.16M33.36M51.33M
Cost of Revenue3.68M3.99M4.07M9.26M17.56M
Gross Profit18.26M16.68M17.09M24.1M33.77M
Gross Margin83.2%80.7%80.8%72.2%65.8%
Research & Development88K98K139K021.37K
Selling, General & Admin5.11M4.4M5.43M12.24M16.3M
Operating Expenses6.45M5.63M5.56M16.26M16.97M
Depreciation & Amortization701K989K1.23M4.02M7.23M
EBITDA13.66M12.04M11.53M11.87M24.1M
EBITDA Margin62.2%58.2%54.5%35.6%46.9%
Operating Income11.82M12.04M11.53M7.85M16.8M
Operating Margin53.9%58.2%54.5%23.5%32.7%
Interest Income12K464K1.87M330K0
Interest Expense92K0001.19M
Other Income / Expenses(2M)(560K)1.15M(4.89M)661.38K
Income Before Tax11.06M11.48M12.68M2.96M17.46M
Pre-Tax Margin50.4%55.5%59.9%8.9%34.0%
Income Tax Expense3.3M(15.16M)(7.7M)(8.59M)(10.34M)
Net Income7.76M26.64M20.38M11.55M27.81M
Net Margin35.4%128.8%96.3%34.6%54.2%
EPS (Basic)0.291.060.800.471.09
EPS (Diluted)0.291.040.800.471.07
Weighted Avg Shares26.6M25.13M25.48M24.72M25.48M
Weighted Avg Shares (Diluted)26.83M25.59M25.42M24.57M25.99M

Cipher Pharmaceuticals Inc.

TSX:CPH.TO

Intrinsic Alpha fair value

Locked

Current Price

$13.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.